This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Poor prognostic indicators include onset of disease in childhood, high urea, persistent proteinuria, evidence of arteritis, cardiopulmonary and CNS involvement, and necessity for long-term corticosteroid therapy.

  • 5 year survival is more than 90% but although SLE survival has improved over the last 40 years, people with SLE still die years younger than average in the UK (1)
  • the most common cause of mortality is cardiovascular disease, followed closely by infection and severe disease activity (2)
  • the risk of death due to malignancy is not increased (3)

References

  1. M Zen et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. European Journal of Internal Medicine. Volume 112. p45-51 June 2023
  2. Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016 Apr;18(4):21.
  3. Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.